ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor)Conference call scheduled for October 01, 2007, 2007 at 1:00 p.m. (Eastern); simultaneous webcast at www.adventrx.com
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, today announced that it will host a conference call and webcast on Monday, October 1st, 2007 to discuss results from its Phase 2b clinical trial of ANX-510, or CoFactor, for the treatment of metastatic colorectal cancer. Evan M. Levine, chief executive officer of ADVENTRX, will host the conference call.
The conference call may be accessed by dialing (800) 665-0430 for domestic callers and (913) 312-0402 for international callers. The webcast will be available live via the Internet by accessing ADVENTRX's web site at www.adventrx.com under "Investors". Replays of the webcast will be available for 30 days, and a phone replay will be available through October 2, 2007 by dialing (888) 203-1112 and entering the passcode 8640821.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. More information can be found on ADVENTRX's web site at www.adventrx.com.
CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: October 2007